• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cosmos Health Inc (NQ: COSM )

    0.7196 -0.0404 (-5.32%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 655,862
    Open 0.7699
    Bid (Size) 0.7301 (5)
    Ask (Size) 0.7366 (11)
    Prev. Close 0.7600
    Today's Range 0.7101 - 0.7866
    52wk Range 0.4677 - 1.650
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cosmos Health’s Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%
    Via ACCESSWIRE
    How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
    How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit 
    Via News Direct

    Performance

    YTD
    -47.47%
    -47.47%
    1 Month
    -3.07%
    -3.07%
    3 Month
    -28.04%
    -28.04%
    6 Month
    +6.80%
    +6.80%
    1 Year
    -37.43%
    -37.43%

    More News

    Read More
    Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands
    Via ACCESSWIRE
    Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins
    Via ACCESSWIRE
    Why Cosmos Health Stock Is Moving Higher Wednesday
    Via Benzinga
    COSM Stock Earnings: Cosmos Health Reported Results for Q2 2024
    Via InvestorPlace
    Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits
    Via ACCESSWIRE
    Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion
    Via ACCESSWIRE
    Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments
    Via ACCESSWIRE
    Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price
    Via ACCESSWIRE
    Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar
    Via ACCESSWIRE
    EXCLUSIVE: Virax Biolabs Inks Distribution Pact For Mpox Diagnostic Kits In Europe And Middle East
    Via Benzinga
    Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements
    Via ACCESSWIRE
    Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE
    Via ACCESSWIRE
    Cosmos Health Holds EU Distribution Rights for Virax Biolabs’ Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits
    Via ACCESSWIRE
    Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs. H1 2023
    Via ACCESSWIRE
    Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit
    Via ACCESSWIRE
    Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market
    Via ACCESSWIRE
    Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share
    Via ACCESSWIRE
    Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar
    Via ACCESSWIRE
    Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland
    Via ACCESSWIRE
    Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity
    Via ACCESSWIRE
    Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units
    Via ACCESSWIRE
    Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule
    Via ACCESSWIRE
    Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.